• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF

tetano

Editor, Senior Moderator
Vaccine. 2019 Jul 26. pii: S0264-410X(19)30955-7. doi: 10.1016/j.vaccine.2019.07.057. [Epub ahead of print]
[h=1]Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF.[/h] Venereo-S?nchez A[SUP]1[/SUP], Fulton K[SUP]2[/SUP], Koczka K[SUP]3[/SUP], Twine S[SUP]2[/SUP], Chahal P[SUP]2[/SUP], Ansorge S[SUP]2[/SUP], Gilbert R[SUP]4[/SUP], Henry O[SUP]5[/SUP], Kamen A[SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] One of the concerns associated with the use of influenza virus-like particles (VLPs) as vaccine candidate or delivery system is their heterogeneous composition. Enveloped VLPs take up the host cell membrane at the budding site carrying out not only the viral antigenic proteins but also host proteins. In addition, the intrinsic nature of cells to produce membrane derived vesicles or extracellular vesicles (EVs), which have similar size to the VLPs, makes VLP purification process challenging. To further characterize these particles and identify proteins that are unique to each population, comparative proteomic analyses were completed to ultimately provide guidance for rational design of separation protocols. The VLPs were produced in suspension and serum free media by transient transfection of an inducible clone of a Human Embryonic Kidney (HEK-293SF) cells expressing HA and NA (H1N1/A/Puerto Rico/8/34), with a plasmid containing the gag gene of HIV-1 fused to GFP. EVs were produced independently from the non-transformed HEK-293SF cell line as a control for comparative studies. Both preparations were characterized for total nucleic acids and protein concentrations and extensively analyzed by nanoLC-MS/MS for their protein compositions. The proteomic analyses showed that aside from the recombinant VLP proteins, nucleolin was the most abundant host cell protein uniquely identified within VLPs (considering the MASCOT score value) while lactotransferrin and heat shock protein 90 were the most abundant proteins in EVs. Overall, this comparative study identifies potential target proteins as specific markers to guide VLP purification and discusses the biogenesis of enveloped particles released in HEK-293 cell suspension cultures emphasizing on the biological functions of host cell proteins identified.
Copyright ? 2019. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Exosomes; Extracellular vesicles; HEK-293SF; Influenza vaccine; Virus-like particles; nLC-MS/MS

PMID: 31358407 DOI: 10.1016/j.vaccine.2019.07.057
 
Back
Top Bottom